Nicotine Reduces Antipsychotic-Induced Orofacial Dyskinesia in Rats

Tanuja Bordia, J.M. McIntosh and Maryka Quik

Center for Health Sciences, SRI International, 333 Ravenswood Ave, California 94025, USA (T.B., M.Q.) and Departments of Biology and Psychiatry, University of Utah, Salt Lake City, Utah, USA (J.M.M.)
RUNNING TITLE PAGE

Running Title: Nicotine and tardive dyskinesia

Corresponding author: Address correspondence and reprint request to Maryka Quik, Center for Health Sciences, SRI International, 333 Ravenswood Ave, California 94025, USA. Tel. 1-650-859-6112; fax 1-650-859-5099. E-mail address: maryka.quik@sri.com

Number of:

pages of text, 29;
tables, 3;
figures, 4;
references, 47.

Number of words in:

abstract, 250;
introduction, 609;
discussion, 1384.

ABBREVIATIONS: VCMs, vacuous chewing movements; ANOVA, analysis of variance; nAChRs, nicotinic acetylcholine receptors; $[^{125}\text{I}]$RTI-121, $[^{125}\text{I}]$-3β-(4-iodophenyl)tropane-2β-carboxylic acid isopropyl ester; *, the asterisk indicates the possible presence of other nicotinic subunits in the receptor complex.

Recommended section assignment: Behavioral Pharmacology
ABSTRACT

Antipsychotics are an important class of drugs for the management of schizophrenia and other psychotic disorders. They act by blocking dopamine receptors; however, since these receptors are present throughout the brain, prolonged antipsychotic use also leads to serious side effects. These include tardive dyskinesia, repetitive abnormal involuntary movements of the face and limbs for which there is little treatment. Here we investigated whether nicotine administration could reduce tardive dyskinesia, since nicotine attenuates other drug-induced abnormal movements. We used a well-established model of tardive dyskinesia, in which rats injected with the commonly used antipsychotic haloperidol develop vacuous chewing movements (VCMs) that resemble human orofacial dyskinesias. Rats were first administered nicotine (minipump 2 mg/kg/d). Two wk later, they were given haloperidol (1 mg/kg sc) once daily. Nicotine treatment reduced haloperidol-induced VCMs by ~20% after 5 wk, with a significant ~60% decline after 13 wk. There was no worsening of haloperidol-induced catalepsy. To understand the molecular basis for this improvement, we measured the striatal dopamine transporter and nAChRs. Both haloperidol and nicotine treatment decreased the transporter and α6β2* nAChRs when given alone, with no further decline with combined drug treatment. By contrast, nicotine alone increased, while haloperidol reduced, α4β2* nAChRs in both vehicle and haloperidol-treated rats. These data suggest that molecular mechanisms other than those directly linked to the transporter and nAChRs underlie the nicotine-mediated improvement in haloperidol-induced VCMs in rats. The present results are the first to suggest that nicotine may be useful for improving the tardive dyskinesia associated with antipsychotic use.
Introduction

Tardive dyskinesia is a serious side effect of long-term antipsychotic treatment for schizophrenia and other psychotic disorders. Antipsychotics are drugs with dopamine (DA) antagonist properties that form the mainstay of treatment for schizophrenia. They exert their beneficial effect by dampening excess dopaminergic activity, which is currently of unknown pathophysiological origin (Turrone et al., 2003; Seeman, 2010; Aia et al., 2011; Gershanik and Gomez Arevalo, 2011; Tarsy et al., 2011). Antipsychotics are effective in alleviating psychosis. However, their long-term use also leads to the development of abnormal involuntary movements or tardive dyskinesia, which can be very disruptive and eventually debilitating. Dyskinesia is quite common with an incidence of up to 24% with continued treatment (Correll et al., 2004; Aia et al., 2011; Gershanik and Gomez Arevalo, 2011; Tarsy et al., 2011). Since schizophrenia has a prevalence rate of 0.5%, tardive dyskinesia afflicts a considerable proportion of the population (Saha et al., 2005).

The development of tardive dyskinesia with antipsychotic use prompted a search for novel drugs with fewer extrapyramidal side effects. The second-generation antipsychotics are associated with a reduced risk of tardive dyskinesia; however, they still develop particularly in older adults, probably because the mechanisms that improve psychoses overlap with those that result in tardive dyskinesia (Correll et al., 2004; Tarsy et al., 2011). In addition, second generation drugs are associated with side effects including weight gain and severe disturbances in lipid and glucose regulation (Tandon et al., 2008; Volavka and Citrome, 2009). There is thus a critical need for better treatment options for psychotic disorders, or at least to reduce the side effects that develop with their use.

Our recent studies have shown that nicotine attenuates the dyskinesias or abnormal...
involuntary movements that develop with long term L-dopa treatment for Parkinson's disease. Nicotine decreased L-dopa-induced dyskinesias in parkinsonian nonhuman primates, when given either before the onset of dyskinesias or when they were established (Quik et al., 2007a). Similar results were obtained in parkinsonian rat and mouse models of L-dopa-induced dyskinesias, attesting to the robustness of the effect of nicotine across species (Bordia et al., 2008; Bordia et al., 2010; Huang et al., 2011a; Huang et al., 2011b). Nicotine reduced dyskinesias when given via several modes of administration, including drinking water, minipumps or injection (Bordia et al., 2008; Bordia et al., 2010; Huang et al., 2011a; Huang et al., 2011b). Several of these treatment paradigms readily lend themselves to use in patients, for instance, as an oral formulation or a slow release mode (nicotine patch). Importantly, nicotine did not worsen the anti-parkinsonian effect of L-dopa in any species.

Antipsychotic administration resembles L-dopa treatment in that both lead to abnormal involuntary movements possibly due to an enhanced dopaminergic tone (Barroso-Chinea and Bezard, 2010; Cenci and Konradi, 2010; Gershanik and Gomez Arevalo, 2011). L-dopa-induced dyskinesias arise because of the increased conversion of L-dopa to DA. Antipsychotics may enhance dopaminergic activity because of a compensatory antagonist-induced DA receptor upregulation. Based on this comparison, we hypothesized that nicotine might also reduce antipsychotic-induced tardive dyskinesia.

To investigate this possibility, we tested the effect of nicotine in a rat model of tardive dyskinesia, which involved injection of the commonly used antipsychotic haloperidol. This model shares many characteristics typical of tardive dyskinesia in humans (Turrone et al., 2002). The present results show that long-term nicotine treatment reduces haloperidol-induced abnormal involuntary movements or vacuous chewing movements (VCMs) in rats. Molecular studies,
including measurement of the DA transporter (DAT), α4β2* and α6β2* nAChRs, were done as an approach to understand the mechanisms associated with the changes in behavior. Overall, these data suggest that nicotine or nAChR drugs may be useful for the treatment of antipsychotic-induced tardive dyskinesia in humans.

Materials and methods

Animals. Adult male Sprague-Dawley rats weighing ~250 g were purchased from Charles River Laboratories, Inc (Wilmington, MA, USA). They were housed two per cage, in a temperature- and humidity-controlled environment under a 12 h light-dark cycle with free access to food and water. All procedures conformed to the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee.

Drug Treatments. One set of 36 rats was used for all behavioral and biochemical experiments. Following habituation, the rats were randomly divided into two groups. Both groups were surgically implanted with osmotic minipumps (Alzet model 2006, delivery rate, 0.15 µl/h; Durect Corporation, Cupertino, CA) filled with either vehicle (water) or nicotine (2 mg/kg/day; free base, Sigma-Aldrich Co., St. Louis, MO), as described (Bordia et al., 2008). Plasma cotinine levels were similar to those in moderate smokers (Matta et al., 2007), suggesting that the nicotine dose is one that would be tolerated in humans. Two wk after the start of nicotine treatment a subset of rats from both vehicle and nicotine-treated groups were injected with haloperidol (1 mg/kg, sc; Sigma-Aldrich Co., St. Louis, MO) or vehicle (water) once daily (5 d per wk) throughout the entire study. This was followed by a 5 wk nicotine withdrawal period, which was initiated by surgical removal of the nicotine-containing minipumps. The rats were then given various doses of nicotine (0.1 - 0.3 mg/kg free base, sc) or saline once only or
once daily for 4 d. They were then implanted with new minipumps containing nicotine (2 mg/kg/d) or vehicle, after which they were euthanized.

**Haloperidol-induced Vacuous Chewing Movements (VCMs).** Rats were evaluated for haloperidol-induced VCMs, as described (Rogoza et al., 2004; Schleimer et al., 2005). These abnormal movements, which resemble human orofacial dyskinesias, are characterized by purposeless mouth openings in a vertical plane, with or without tongue protrusion and jaw tremors that are presented as high frequency fasciculations of the mouth or jaw (Turrone et al., 2003). The rats were individually placed in a circular plexiglass chambers for 15 min to allow them to adapt to the novel environment. Mirrors were strategically placed around the chamber to evaluate VCMs that arose when the animal faced away from the observer. After habituation, rats were injected with haloperidol, and the number of VCMs counted for 5 min, with average scores of ≥8 VCMs/5 min considered positive for abnormal movements (Turrone et al., 2003). VCMs were assessed every second week until week 13, after which they were rated on a weekly basis.

**Haloperidol-induced catalepsy.** The bar test was used to quantify haloperidol-induced catalepsy. This test measures the ability of the animal to respond to drug-induced immobility (Kuschinsky and Hornykiewicz, 1972). Thirty min before treatment, rats were rated for baseline catalepsy by placing their front paws over a 10-cm high horizontal bar. Cataleptic measurements were defined as the time taken to remove the paw from the horizontal bar within a one-min period. After baseline measurements, the rats were injected with haloperidol. Ten min after injection, catalepsy was again assessed.

**Autoradiography.** Rats were killed by decapitation 90 min after vehicle or haloperidol injection (Samaha et al., 2008). The brains were immediately frozen in isopentane on dry ice and stored at −80°C. When required, 8-µm-thick coronal sections were cut from the frozen half of the
brain using a cryostat (Leica Microsystem, Deerfield, IL, USA) at -18°C. The cut sections were
thaw mounted onto Superfrost Plus™ slides (Fisher, Pittsburg, PA, USA), air dried and stored at
-80°C for autoradiography. After each experiment, slides were air dried and exposed to Kodak
MR film (Perkin Elmer Life Sciences, Boston, MA) along with [3H] standards (GE Healthcare,
Chalfont St. Giles, Buckinghamshire, UK).

[125I]RTI-121 Binding. Dopamine transporter (DAT) levels were measured using [125I]RTI-
121 (specific activity, 2200 Ci/mmol; PerkinElmer Analytical and Life Sciences, Boston, MA,
USA) autoradiography as previously described (Bordia et al., 2008). Sections were preincubated
2 x for 15 min in buffer (50 mM Tris-HCl, pH 7.4, 120 mM NaCl, 5 mM KCl) and then
incubated for 2 h with 50 pM [125I]RTI-121 in the same buffer also containing 0.025% BSA and
1 µM fluoxetine. Sections were washed 4 x 15 min in ice cold buffer, 1 x 10 s in ice cold
deionized H2O. Nonspecific binding was determined in the presence of the DA uptake inhibitor
nomifensine (100 µM).

[125I]α-CtxMII Binding. α6β2* nAChR levels were measured using [125I]α-CtxMII (specific
activity, 2200 Ci/mmol), as described (Quik et al., 2003). Sections were preincubated for 15 min
in binding buffer (20 mM Hepes Buffer, 144 mM NaCl, 1.5 mM KCl, 2.0 mM CaCl2, 1.0 mM
MgSO4), plus 1.0 mM phenylmethylsulfonyl fluoride. This was followed by a 1 h incubation in
binding buffer plus 0.5% BSA, also containing 5 mM EDTA, 5 mM EGTA, 10 µg/ml each of
aprotinin, leupeptin, pepstatin A, and 0.5 nM [125I]-α-CtxMII. The assay was terminated by
washing the slides for 10 min, in ice-cold binding buffer at RT, 2x 10 min in 0.1X buffer at 0°C
and two final 5 s washes in ice-cold deionized water. Nicotine (100 µM) was used to determine
nonspecific binding.
[^125I]Epibatidine Binding. α4β2* nAChRs levels were measured using [^125I]epibatidine (specific activity, 2200 Ci/mm mol; PerkinElmer Analytical and Life Sciences, Boston, MA, USA) (Quik et al., 2003). Thawed sections were pre-incubated at RT for 15 min in buffer containing 50 mM Tris, pH 7.5, 120 mM NaCl, 5 mM KCl, 2.5 mM CaCl₂, and 1.0 mM MgCl₂. This was followed by a 40 min incubation with 0.015 nM [^125I]epibatidine without or with 100 nM α-CtxMII to define α4β2* nAChRs. Sections were washed 2 x 5 min in ice-cold buffer, 1 x 10 s in ice cold deionized H₂O. Nicotine (100 µM) was used to determine nonspecific binding.

Data Analysis. For quantification of the optical densities from autoradiographic images, we used the ImageQuant system (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK). Specific binding (total binding minus nonspecific binding) was converted to fmol/mg tissue using standard curves generated from radioactive [³H] standards that were simultaneously exposed to the films. The standards were calibrated for [^125I] autoradiography, as described (Artymyshyn et al., 1990). The optical density readings for the samples fell within the linear range of the film. The receptor levels for any one animal were obtained from at least two independent experiments using two to three consecutive sections per experiment.

Statistical Analysis. All statistics were conducted using GraphPad Prism (Graph Pad Software Co., San Diego, CA, USA). Comparisons were performed using two-way analysis of variance (ANOVA), followed by a Bonferroni post hoc test. A level of 0.05 was considered significant. Values are expressed as the mean ± SEM of the indicated number of rats, and represent data pooled from up to two separate experiments.
Results

Chronic Nicotine Treatment Reduces Haloperidol-Induced VCMs. Rats were implanted with minipumps containing vehicle or nicotine (2 mg/kg/day). Such a nicotine regimen results in cotinine levels of ~300 ng/ml (Bordia et al., 2008), which is similar to those in moderate smokers (Matta et al., 2007). Two wk later, they were injected sc once daily with 1 mg/kg haloperidol or vehicle, as outlined in Fig. 1. They were rated for VCMs bi-weekly until wk 13, and then every wk thereafter by a blinded rater. Administration of haloperidol resulted in the development of significant VCMs by 7 wk of treatment, which plateaued at ~13 wk, consistent with previous studies (Turrone et al., 2002). Chronic nicotine dosing significantly (p < 0.01) decreased VCMs after 13 wk of haloperidol treatment, with a trend for a decline starting at 5 wk (Fig. 2). Two-way ANOVA yielded a significant main effect of both nicotine and haloperidol treatment (p < 0.001), as well as a significant interaction (p < 0.01). The extended time course suggests that the effect of nicotine on haloperidol-induced VCMs involves long-term molecular changes.

Nicotine reduces haloperidol-induced abnormal involuntary movements in rats during the light and dark phase of the light/dark cycle. Because rats are nocturnal, we also evaluated haloperidol-induced VCMs in the dark phase of the light-dark cycle to determine if these movements were altered by diurnal rhythms (Table 1). Haloperidol treatment resulted in comparable levels of VCMs in the dark and light phase. Moreover, nicotine treatment reduced VCMs (p < 0.001) to a similar extent in either phase, with a significant main effect of nicotine (p < 0.01) and haloperidol treatments (p < 0.001), as assessed by ANOVA. Thus, the magnitude of haloperidol-induced VCMs and the effect of nicotine appear to be independent of circadian rhythms.

Nicotine removal worsens haloperidol-induced VCMs, while its re-exposure reduces...
**VCMs** The results in Fig. 2 show that nicotine pre-treatment reduces the development of haloperidol-induced VCMs. An important question that arises is the reversibility of the nicotine-mediated decline in haloperidol-induced VCMs. To address this, the nicotine-containing minipumps were removed and VCMs rated weekly thereafter, with haloperidol treatment continued. The results in Fig. 3 show that there was a gradual increase in VCMs with nicotine withdrawal, reaching levels similar to that of the vehicle-treated group 5 wk after nicotine removal.

We next tested whether nicotine re-administration would decrease haloperidol-induced VCMs in the rats previously exposed to nicotine. We first evaluated the efficacy of a single, acute dose of either 0.1 or 0.3 mg/kg nicotine sc injected 10 min before haloperidol (Table 2). However, no decline was observed in haloperidol-induced VCMs with either dose given acutely.

We also tested the effect of a slightly longer nicotine treatment regimen (once daily injections for 4 d), with a similar lack of effect. The rats were then re-implanted with nicotine-containing minipumps (2 mg/kg/day) (Fig. 3). A significant decrease in haloperidol-induced VCMs (p < 0.05) was observed after two wk of chronic treatment as compared to the vehicle-treated group. These data suggests that continued nicotine dosing is required to maintain its beneficial effects against VCMs.

**Chronic nicotine treatment does not reduce haloperidol-induced catalepsy.** In addition to VCMs, haloperidol treatment also induces catalepsy. To test if nicotine modified this behavior, we used the bar test. This test measures the time required for the rat to remove its forelimbs from an elevated horizontal bar 10 min after haloperidol compared to vehicle treatment (Kuschinsky and Hornykiewicz, 1972). Haloperidol-induced catalepsy (descent latency in seconds) was similar with nicotine and vehicle treatments. Thus, nicotine selectively affects VCMs (Table 3).
Chronic nicotine and haloperidol treatments decrease the striatal DA transporter. Previous studies measuring tyrosine hydroxylase immunoreactivity had suggested that haloperidol induces VCMs by downregulating nigrostriatal DA neurons (Marchese et al., 2002; Zhang et al., 2007; Reynolds et al., 2011). To investigate whether haloperidol modulated dopaminergic measures in our studies, we measured the DA transporter (DAT), a DA nerve terminal marker (Quik et al., 2006). Haloperidol treatment reduced (p < 0.001) striatal DAT levels (Fig. 4 top), consistent with previous studies measuring tyrosine hydroxylase immunoreactivity (Marchese et al., 2002; Zhang et al., 2007; Reynolds et al., 2011). The long-term nicotine treatment also decreased DAT (p < 0.01). ANOVA showed a significant interaction (p < 0.05) between nicotine and haloperidol treatments, with results indicating that the combined effect of nicotine and haloperidol was not additive (Fig. 4 top). These data suggest that the nicotine- and haloperidol-induced declines in DAT share a common mechanism.

Nicotine and/or haloperidol treatments modulate striatal $\alpha_6\beta_2^*$ and $\alpha_4\beta_2^*$ nAChR levels. Since nicotine generally exerts its CNS effects by acting at nAChRs, we next investigated the impact of chronic nicotine treatment on $\alpha_6\beta_2^*$ and $\alpha_4\beta_2^*$ nAChRs, the primary subtypes in striatum. The effect on binding of $\alpha_6\beta_2^*$ nAChRs, measured using $[^{125}\text{I}]\alpha$-CtxMII, is shown in Fig. 4 (middle). Nicotine reduced $\alpha_6\beta_2^*$ nAChRs (p < 0.001), consistent with studies showing that it down regulates this subtype (Quik et al., 2006). Haloperidol treatment also decreased $\alpha_6\beta_2^*$ nAChRs (p < 0.01). Two-way ANOVA yielded a significant interaction (p < 0.01) between nicotine and haloperidol treatments. These data suggest that the nicotine- and haloperidol-induced declines in $\alpha_6\beta_2^*$ nAChRs occur via a similar mechanism, analogous to our observations for DAT.

We also measured $\alpha_4\beta_2^*$ receptors, the other major nAChR subtype in striatum using
[\textsuperscript{125}I]epibatidine binding in the presence of $\alpha$-CtxMII (Fig. 4 bottom). Chronic haloperidol treatment alone led to a small but significant decrease ($p < 0.001$) in receptor levels in the striatum. This decline was region specific with no decrease in the cortex (vehicle, $5.8 \pm 0.23$: haloperidol, $5.3 \pm 0.07$ fmol/mg). Chronic nicotine treatment alone increased ($p < 0.001$) $\alpha_4\beta_2^*$ nAChRs in both striatum and in cortex (nicotine, $7.2 \pm 0.13$: nicotine plus haloperidol; $7.6 \pm 0.06$ fmol/mg), in agreement with previous findings (Quik et al., 2011). In addition, nicotine administration increased $\alpha_4\beta_2^*$ nAChRs in striatum of haloperidol-treated rats ($p < 0.001$). Two-way ANOVA yielded a significant ($p < 0.01$) main effect of both nicotine and haloperidol treatments, with no significant interaction. Thus, haloperidol treatment decreased in $\alpha_4\beta_2^*$ receptors in both vehicle- and nicotine-treated rats.

**Discussion**

The present results are the first to show that nicotine administration reduces the severity of haloperidol-induced VCMs in a rat model of tardive dyskinesia. Nicotine was equally effective in reducing VCMs in either phase of the light-dark cycle, attesting to the robustness of this effect. Time course studies suggest that the effect of nicotine on haloperidol-induced VCMs involves long-term molecular changes. These data support the idea that nicotine or nAChR drugs may be useful for reducing antipsychotic-induced tardive dyskinesia.

For our studies, we used an established animal model of tardive dyskinesias, in which rats are administered the commonly used antipsychotic haloperidol for several months (Turrone et al., 2002). Rats treated chronically with antipsychotics develop VCMs that share many characteristics typical of tardive dyskinesia, including similarities in appearance, developmental time course and response to DA drugs (Waddington, 1990). Although one of the best animal
models, there are limitations as VCMs have been reported to normalize after haloperidol removal in some studies (Marchese et al., 2002; Zhang et al., 2007), while antipsychotic-induced tardive dyskinesia in humans may be irreversible (Gershanik and Gomez Arevalo, 2011).

Experiments were first done to determine whether the nicotine-mediated reduction in haloperidol-induced VCMs developed on an acute basis or over the long-term. Nicotine did not attenuate haloperidol-induced VCMs when administered as a single acute dose. Once daily nicotine injection for 4 days also failed to improve VCMs. Instead, two weeks of chronic nicotine administration was necessary for a significant reduction in VCMs, while 4-5 weeks of nicotine removal was required before its beneficial effects were lost. These combined data suggest that nicotine-mediated effects on haloperidol-induced VCMs involve long-term molecular and/or cellular mechanisms.

A chronic morphological change associated with the development of tardive dyskinesia is drug-induced declines in tyrosine hydroxylase positive neurons nigrostriatal dopaminergic neurons (Marchese et al., 2002; Andreassen et al., 2003; Zhang et al., 2007; Reynolds et al., 2011). Haloperidol treatment causes a shrinkage or loss of tyrosine hydroxylase immunoreactive neurons in the substantia nigra and a reduction in tyrosine hydroxylase immunoreactivity in rat striatum, which correlates with the development of VCMs (Levinson et al., 1998; Mazurek et al., 1998; Marchese et al., 2002; Zhang et al., 2007). These changes selectively occur in the nigrostriatal pathway, with no declines in the mesolimbic DA system (Reynolds et al., 2011). The reduced tyrosine hydroxylase immunoreactivity in the striatum and the presence of VCMs were both normalized after ~1 month of haloperidol removal, suggesting a causal link (Marchese et al., 2002; Zhang et al., 2007). Interestingly, a more recent study showed that the haloperidol-induced decline in tyrosine hydroxylase immunoreactive cells in the nigra was blocked by
administration of a DAT blocker (Reynolds et al., 2011). These data could suggest that haloperidol-induced morphological changes are due to an increase in DA turnover, which leads to elevated intracellular DA, subsequent inhibition of complex I and enhanced oxidative stress.

In contrast to these detrimental effects of haloperidol, extensive in vitro and in vivo studies show that nicotine protects against nigrostriatal dopaminergic damage. Chronic nicotine treatment improves neurotoxin-induced dopaminergic degeneration in rodents and nonhuman primates (Quik et al., 2007b; Picciotto and Zoli, 2008). Nicotine is thought to exert this effect by acting at CNS nAChRs. These are pentameric ion channels composed of different α subunits (α2-α10) or of α and β subunits (β2-β4) (Albuquerque et al., 2009; Gotti et al., 2009; Millar and Gotti, 2009; Changeux, 2010; Quik and Wonnacott, 2011). The principle subtypes in the peripheral nervous system are the α3β4* and α7 nAChRs, while the α4β2*, α6β2* and α7 nAChRs are the primary ones in the nigrostriatal pathway. The asterisk indicates the possible presence of other subunits in the receptor complex. The α6β2* nAChR subtypes have a restricted CNS distribution including dopaminergic pathways, while the α4β2* subtypes are widely distributed in the brain, and also present on dopaminergic nerve terminals (Quik et al., 2011; Quik and Wonnacott, 2011; Threlfell and Cragg, 2011).

The present results showing a decline in striatal DAT with haloperidol treatment complement previous work demonstrating a loss in tyrosine hydroxylase immunoreactivity in the nigrostriatal pathway (Marchese et al., 2002; Zhang et al., 2007; Reynolds et al., 2011). This loss in tyrosine hydroxylase immunoreactivity has been attributed to haloperidol-induced down regulation. Chronic nicotine treatment via minipump also decreased DAT. Since nicotine is generally thought to protect against nigrostriatal damage (Quik et al., 2007b), this decline may reflect transporter downregulation. Such an interpretation is consistent with other studies showing that
drugs such as amphetamine and methylphenidate also downregulate DAT (Madras et al., 2005). Interestingly, the effect of combined nicotine and haloperidol treatments was similar to that with either drug alone. These data suggest that nicotine and haloperidol may reduce DAT via an analogous mechanism of action, possibly downregulation.

The drug-induced changes in α6β2* nAChRs were very similar to those in DAT. This analogous regulation may relate to the fact that both DAT and α6β2* nAChRs share a similar localization on dopaminergic nerve terminals in the striatum. These data contrast with the effects of nicotine and haloperidol on α4β2* receptors, the other major nAChR subtype in striatum. These differential changes in α4β2* as compared to α6β2* nAChRs may relate to their differential cellular localization, with only a small proportion (20%) of α4β2* receptors present on DA terminals, and the greater majority (80%) on other striatal elements (Quik et al., 2003). Chronic haloperidol treatment alone significantly decreased striatal α4β2* receptor binding in both vehicle- and haloperidol-treated rats. Furthermore, chronic nicotine treatment alone increased α4β2* nAChRs in the vehicle-treated group, consistent with previous findings (Quik et al., 2011), and also elevated α4β2* nAChRs in striatum of haloperidol-treated rats.

How these molecular changes in DAT, α6β2* nAChRs and/or α4β2* nAChRs relate to nicotine’s beneficial action against antipsychotic-induced VCMs is an important question. The current studies did not identify unique changes in α4β2* nAChRs with nicotine and haloperidol treatment that might explain the beneficial effect of nicotine to reduce VCMs. Moreover, the observations that DAT and α6β2* nAChR levels were similar with nicotine or haloperidol treatment alone, and with combined nicotine and haloperidol treatment suggest that these measure are not directly associated with the nicotine-mediated decline in haloperidol-induced VCMs. On the other hand, the DAT and nAChR studies were done at sub-saturating
concentration of radioligand. Studies at higher radioligand concentrations may yield information about potential changes in maximal responsiveness under the different treatment conditions. Overall, the current data indicate changes other than those directly at the DAT and nAChR level underlie the nicotine-mediated improvement in haloperidol-induced VCMs in rats. This may include adaptive changes in intracellular signaling mechanisms associated with nAChRs and/or in other neurotransmitter systems linked to the nicotinic cholinergic and dopaminergic systems.

Clinical trials have been done to investigate the link between smoking and tardive dyskinesias, with conflicting results (Yassa et al., 1987; Menza et al., 1991; Nilsson et al., 1997; Diehl et al., 2009; Zhang et al., 2011). In studies in which smoking correlated with the severity of tardive dyskinesia, data interpretation was complicated by findings that tardive dyskinesia was also associated with significantly higher exposure to antipsychotics, frequencies of psychiatric morbidity and/or alcohol dependence (Yassa et al., 1987; Nilsson et al., 1997). In another study, patients who smoked received significantly higher doses of antipsychotics but did not have more frequent or more severe tardive dyskinesia (Menza et al., 1991). Altogether, these data indicate that further work is required to understand the relationship between smoking and tardive dyskinesia.

In summary, our data show that nicotine treatment decreases haloperidol-induced VCMs in an established rat model of tardive dyskinesia. The demonstration that nicotine removal leads to a return of VCMs, while nicotine re-exposure reduced haloperidol-induced VCMs, suggests a causal relationship. These data have clinical application for the treatment of tardive dyskinesias associated with long-term antipsychotic treatment using nicotine. Importantly, multiple nicotine formulations are currently available in humans for other indications primarily smoking cessation, including the nicotine patch, gum, lozenge, nasal spray and nasal inhalant (Matta et al., 2007).
One or other of these has potential in the treatment of tardive dyskinesia. A clinical trial in subjects with tardive dyskinesias would be necessary for development of the optimal therapy. Alternatively, the development of subtype selective nAChR drugs may better target the receptors directly linked to the development of tardive dyskinesias with optimal beneficial results and a minimum of side effects.
Authorship Contributions

Participated in research design: Bordia, Quik
Conducted experiments: Bordia
 Contributed new reagents or analytic tools: McIntosh
 Performed data analysis: Bordia, Quik
 Wrote or contributed to the writing of the manuscript: Bordia, McIntosh, Quik
References


Madras BK, Miller GM and Fischman AJ (2005) The dopamine transporter and attention-
deficit/hyperactivity disorder. *Biol Psychiatry* **57**:1397-1409.


Seeman P (2010) Dopamine D2 receptors as treatment targets in schizophrenia. *Clin Schizophr Relat Psychoses* **4**:56-73.


Footnotes

This work was supported by grants from the National Institutes of Health [NS 47162, NS 59910 and MH 53631]. The authors thank Matthew Chin for excellent technical assistance.
Figure legends

Fig. 1. Experimental design depicting the time line and dosing of nicotine and haloperidol treatments. Rats were surgically implanted with minipumps containing vehicle or nicotine (2/mg/kg/day). Two wk later, a subset of rats from the vehicle and nicotine-treated groups was administered vehicle or haloperidol (1 mg/kg, sc) once daily until the end of the study with the nicotine continued. After 3 wk of haloperidol treatment, rats were rated once weekly for haloperidol-induced VCMs throughout the entire course of the study.

Fig. 2. Time course of the nicotine-mediated reduction in haloperidol-induced vacuous chewing movements (VCMs). Rats were implanted with minipumps containing vehicle or nicotine (2 mg/kg/day). Two weeks later, a subset of rats receiving vehicle or nicotine was injected sc once daily with haloperidol (1 mg/kg). They were then evaluated for the development of VCMs at the indicated time points, as described in Materials and Methods. Nicotine treatment significantly reduced the severity of haloperidol-induced VCMs. Values are the mean ± SEM of 6 rats in the vehicle and nicotine-treated and 12 rats in the haloperidol and nicotine + haloperidol-treated groups. Significance of difference from the vehicle-treated control, ###p < 0.001: from the haloperidol-treated group, *p < 0.05, **p < 0.01, ***p < 0.001 using two-way ANOVA followed by a Bonferroni post hoc test.
Fig. 3. Effect of nicotine removal and re-exposure on haloperidol-induced VCMs. Nicotine (2 mg/kg/day) containing minipumps were removed, with haloperidol treatment continued. The rats were then rated for VCMs every wk for 5 wk. Removal of nicotine resulted in a gradual increase in haloperidol-induced VCMs overtime, reaching levels similar to that of the vehicle treated group by 5 wk (left to right). Interestingly, two wk of nicotine (2 mg/kg/day) re-exposure led to a significant reduction in haloperidol-induced VCMs. Values are the mean ± SEM of 6 rats in the vehicle and nicotine-treated and 12 rats in the haloperidol and nicotine + haloperidol-treated groups. Significance of difference from vehicle-treated control, #p < 0.05, ##p < 0.01 ###p < 0.001; from own vehicle-treated group, *p < 0.05, ***p < 0.001 using two-way ANOVA followed by a Bonferroni post hoc test.

Fig. 4. Chronic nicotine and/or haloperidol treatment alters the striatal dopamine transporter, as well as α6β2* and α4β2* nAChR levels. Rats were chronically administered nicotine (2 mg/kg/day) and/or haloperidol (1 mg/kg) as described in Materials and Methods. After treatment, they were killed 90 min after the last injection of haloperidol. Top panel shows striatal dopamine transporter levels measured using [125I]RTI-121. Chronic nicotine and haloperidol treatments resulted in a significant reduction in transporter levels with no further reduction with the combined treatment. The middle panel depicts striatal α6β2* nAChR levels assessed using [125I]α-CtxMII. Both nicotine and haloperidol treatments resulted in significant reductions in α6β2* nAChR levels, with no further decrease with the combined treatment. Striatal α4β2*nAChR levels were determined by measuring binding of [125I]epibatidine in the presence of α-CtxMII. Nicotine treatment increased α4β2* nAChRs in the absence or presence of haloperidol, while chronic haloperidol treatment alone led to a significant decrease in binding.
Values are the mean ± SEM of 6 rats in the vehicle and nicotine-treated and 12 rats in the haloperidol and nicotine + haloperidol-treated groups. Significance of difference from vehicle-treated control, #p < 0.01, ###p < 0.001; from own vehicle-treated group, **p < 0.01, ***p < 0.001 using 2-way ANOVA followed by a Bonferroni test.
TABLE 1

Similar reduction in haloperidol-induced VCMs with chronic nicotine treatment (2 mg/kg/d) in the light or dark phase of the light-dark cycle

Rats were rated for haloperidol-induced VCMs in the light or dark phase of the daily cycle as described in Materials and Methods. Values are the mean ± SEM of 6 rats in the vehicle and nicotine-treated and 12 rats in the haloperidol and nicotine + haloperidol-treated groups. Significance of difference from vehicle-treated control, #p <0.05, ###p <0.001; from vehicle-treated group, ***p < 0.001 using two-way ANOVA followed by a Bonferroni post hoc test

<table>
<thead>
<tr>
<th>Lighting condition</th>
<th>Treatment</th>
<th>Number of VCMs/ 5 min</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Control</td>
</tr>
<tr>
<td>Light</td>
<td>Vehicle</td>
<td>0.4 ± 0.2</td>
</tr>
<tr>
<td></td>
<td>Nicotine</td>
<td>0.3 ± 0.2</td>
</tr>
<tr>
<td>Dark</td>
<td>Vehicle</td>
<td>0.2 ± 0.2</td>
</tr>
<tr>
<td></td>
<td>Nicotine</td>
<td>0.1 ± 0.1</td>
</tr>
</tbody>
</table>
TABLE 2

Effect of acute and subchronic nicotine treatment on haloperidol-induced VCMs

Rats were injected with haloperidol 10 min after nicotine treatment and rated for haloperidol-induced VCMs on wk 22-25 (see Fig. 1). Nicotine treatment had no effect on haloperidol-induced VCMs when administered on an acute (single dose) or subchronic (once daily for 4 d) basis. Values are the mean ± SEM of 6 rats in the vehicle and nicotine-treated and 12 rats in the haloperidol and nicotine + haloperidol-treated groups. Significance of difference from own control, #p < 0.05 using two-way ANOVA followed by a Bonferroni post hoc test.

<table>
<thead>
<tr>
<th>Length of treatment</th>
<th>Treatment</th>
<th>Dose</th>
<th>Number of VCMs/5 min</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Control</td>
</tr>
<tr>
<td>Single dose</td>
<td>Vehicle</td>
<td>--</td>
<td>0.4 ± 0.3</td>
</tr>
<tr>
<td></td>
<td>Nicotine</td>
<td>0.1 mg/kg</td>
<td>0 ± 0</td>
</tr>
<tr>
<td></td>
<td>Vehicle</td>
<td>--</td>
<td>0.4 ± 0.2</td>
</tr>
<tr>
<td></td>
<td>Nicotine</td>
<td>0.3 mg/kg</td>
<td>0 ± 0</td>
</tr>
<tr>
<td>Once daily for 4 d</td>
<td>Vehicle</td>
<td>--</td>
<td>0 ± 0</td>
</tr>
<tr>
<td></td>
<td>Nicotine</td>
<td>0.1 mg/kg</td>
<td>0.2 ± 0.2</td>
</tr>
<tr>
<td></td>
<td>Vehicle</td>
<td>--</td>
<td>0.8 ± 0.4</td>
</tr>
<tr>
<td></td>
<td>Nicotine</td>
<td>0.2 mg/kg</td>
<td>0.2 ± 3.8</td>
</tr>
</tbody>
</table>
TABLE 3

Nicotine treatment had no effect on haloperidol-induced catalepsy

Rats were assessed for haloperidol-induced catalepsy using the bar test, which measures the time taken (latency) for the rat to remove its forelimbs from an elevated horizontal bar. Nicotine or vehicle was injected 10 min before haloperidol treatment. Cataleptic effects of haloperidol were measured for 60 sec, 10 min after haloperidol injection, immediately after rating of the VCMs. Values are the mean ± SEM of 6 rats in the vehicle and nicotine-treated and 12 rats in the haloperidol and nicotine + haloperidol-treated groups. Significance of difference from own control, ##p <0.01, ###p <0.001 using two-way ANOVA followed by a Bonferroni post hoc test.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Length of treatment</th>
<th>Dose</th>
<th>Descent latency (sec)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Control</td>
<td>Haloperidol</td>
</tr>
<tr>
<td>Vehicle</td>
<td>One injection</td>
<td>0.40 ± 0.24</td>
<td>17.1 ± 3.5###</td>
</tr>
<tr>
<td>Nicotine</td>
<td>0.1mg/kg</td>
<td>0.66 ± 0.21</td>
<td>11 ± 2.5##</td>
</tr>
<tr>
<td>Vehicle</td>
<td>Once daily for 4 d</td>
<td>0.20 ± 0.20</td>
<td>19.1 ± 3.4###</td>
</tr>
<tr>
<td>Nicotine</td>
<td>0.1mg/kg</td>
<td>0.51 ± 0.22</td>
<td>18.2 ± 4.6###</td>
</tr>
<tr>
<td>Vehicle</td>
<td>Chronic (minipump)</td>
<td>0.42 ± 0.23</td>
<td>22.7 ± 3.5###</td>
</tr>
<tr>
<td>Nicotine</td>
<td>2 mg/kg/day</td>
<td>0.83 ± 0.30</td>
<td>25.1 ± 2.5###</td>
</tr>
</tbody>
</table>
Nicotine or vehicle treatment

2 mg/kg/day, minipump

withdrawal

0.1-0.3 mg/kg, sc

2 mg/kg/day, minipump

2 0 2 4 6 8 10 16 18 20 22 23 24 25 26 27 28 wk

↑

VCM ratings

Haloperidol (1 mg/kg, sc) or vehicle treatment

Assay

This article has not been copyedited and formatted. The final version may differ from this version.
Figure 3

On nicotine
VCMS scores/5 min

Wk 1 off nicotine

Wk 2 off nicotine

Wk 3 off nicotine

Wk 4 off nicotine

Wk 5 off nicotine

Re-exposure to nicotine for 2 wk

---

Comparison of VCMs scores before and after nicotine treatment or re-exposure to nicotine for 2 weeks.

* p < 0.05
** p < 0.01
*** p < 0.001
Figure 4

Dopamine transporter

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Haloperidol</th>
</tr>
</thead>
<tbody>
<tr>
<td>[125I]-RTI-121 binding (fmol/mg tissue)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>***</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

α6β2* nAChR

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Haloperidol</th>
</tr>
</thead>
<tbody>
<tr>
<td>[125I]-α-CtxMII binding (fmol/mg tissue)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>***</td>
<td></td>
<td></td>
</tr>
<tr>
<td>**</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

α4β2* nAChR

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Haloperidol</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-CtxMII-resistant [125I]epibatidine binding (fmol/mg tissue)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>***</td>
<td></td>
<td></td>
</tr>
<tr>
<td>***</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>